Haemolytic disease of the fetus and newborn

Vox Sanguinis

Volumn 109, Issue 2, 2015, Pages 99-113

  de Haas, M ^a,b   Thurik, F F ^b   Koelewijn, J M ^b,c   van der Schoot, C E ^b  

^a Sanquin Diagnostiek   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Alloimmunisation in pregnancy; Anti D prophylaxis; Fetal genotyping; Haemolytic disease of the fetus and newborn; RBC antigens and antibodies

Indexed keywords

ALLOANTIBODY; ERYTHROCYTE ANTIBODY; ERYTHROCYTE ANTIGEN; IMMUNOGLOBULIN; RHESUS D ANTIBODY; BLOOD GROUP RHESUS SYSTEM;

ALLOIMMUNIZATION; ANTIBODY SPECIFICITY; EXTRAMEDULLARY HEMATOPOIESIS; FETUS DEATH; FETUS HYDROPS; HIGH RISK PATIENT; HUMAN; INTRAUTERINE BLOOD TRANSFUSION; LABORATORY TEST; NEWBORN HEMOLYTIC DISEASE; PATHOPHYSIOLOGY; PRENATAL CARE; PRIORITY JOURNAL; REVIEW; BLOOD GROUP RHESUS SYSTEM; ERYTHROBLASTOSIS, FETAL; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; NEWBORN; PREGNANCY;

ERYTHROBLASTOSIS, FETAL; FEMALE; HUMANS; IMMUNOTHERAPY; INFANT, NEWBORN; PREGNANCY; RH-HR BLOOD-GROUP SYSTEM;

EID: 84937073620     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12265     Document Type: Review

References (107)

1. Daniels G: Blood group antibodies in haemolytic disease of the fetus and newborn; in: Hadley A, Soothill P (eds): Alloimmune Disorders of Pregnancy. Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn. Cambridge, Cambridge University Press, 2002:21-40
2. Franklin IM: Prevention of rhesus haemolytic disease of the fetus and newborn. Lancet 2009; 373:1082
3. Moise KJ: Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med 2008; 13:207-214
4. Mollison PL, Engelfriet CP, Contreras M: Hemolytic disease of the fetus and the newborn; in: Mollison PL, Engelfriet CP, Contreras M (eds): Blood Transfusion in Clinical Medicine, 11th edn. Oxford, UK, Oxford Blackwell Science, 2005:496-545
5. Moise KJ: Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2008; 112:164-176
6. Koelewijn JM, de Haas M, Vrijkotte TG, et al.: One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 2008; 48:1721-1729
7. Koelewijn JM, Vrijkotte TG, van der Schoot CE, et al.: Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008; 48:941-952
8. Illanes S, Soothill P: Management of red cell alloimmunisation in pregnancy: the non-invasive monitoring of the disease. Prenat Diagn 2010; 30:668-673
9. Vaughan JI, Manning M, Warwick RM, et al.: Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 1998; 338:798-803
10. Daniels G, Hadley A, Green CA: Causes of fetal anemia in hemolytic disease due to anti-K. Transfusion 2003; 43:115-116
11. Heathcote DJ, Carroll TE, Flower RL: Sixty years of antibodies to MNS system hybrid glycophorins: what have we learned? Transfus Med Rev 2011; 25:111-124
12. Dajak S, Stefanovic V, Capkun V: Severe hemolytic disease of fetus and newborn caused by red blood cell antibodies undetected at first-trimester screening (CME). Transfusion 2011; 51:1380-1388
13. NICE: NICE issues guidance for RhD-negative women during pregnancy. 2002. Report No.: 2002/024
14. Hackney DN, Knudtson EJ, Rossi KQ, et al.: Management of pregnancies complicated by anti-c isoimmunization. Obstet Gynecol 2004; 103:24-30
15. Joy SD, Rossi KQ, Krugh D, et al.: Management of pregnancies complicated by anti-E alloimmunization. Obstet Gynecol 2005; 105:24-28
16. Hughes LH, Rossi KQ, Krugh DW, et al.: Management of pregnancies complicated by anti-Fy(a) alloimmunization. Transfusion 2007; 47:1858-1861
17. Pate LL, Myers JC, Palma JP, et al.: Anti-Ge3 causes late-onset hemolytic disease of the newborn: the fourth case in three hispanic families. Transfusion 2013; 53:2152-2157
18. Han P, Kiruba R, Ong R, et al.: Haematolytic disease due to ABO incompatibility: incidence and value of screening in an Asian population. Aust Paediatr J 1988; 24:35-38
19. Bhat YR, Kumar CG: Morbidity of ABO haemolytic disease in the newborn. Paediatr Int Child Health 2012; 32:93-96
20. Lin M, Broadberry RE: ABO hemolytic disease of the newborn is more severe in Taiwan than in white populations. Vox Sang 1995; 68:136
21. Toy PT, Reid ME, Papenfus L, et al.: Prevalence of ABO maternal-infant incompatibility in Asians, Blacks, Hispanics and Caucasians. Vox Sang 1988; 54:181-183
22. Daniels G, Finning K, Martin P, et al.: Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn 2009; 29:101-107
23. Daniels G, van der Schoot CE, Olsson ML: Report of the fourth International Workshop on molecular blood group genotyping. Vox Sang 2011; 101:327-332
24. Finning K, Martin P, Summers J, et al.: Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion 2007; 47:2126-2133
25. Legler TJ, Muller SP, Haverkamp A, et al.: Prenatal RhD testing: a review of studies published from 2006 to 2008. Transfus Med Hemother 2009; 36:189-198
26. Muller SP, Bartels I, Stein W, et al.: Cell-free fetal DNA in specimen from pregnant women is stable up to 5 days. Prenat Diagn 2011; 31:1300-1304
27. Scheffer PG, van der Schoot CE, Page-Christiaens GC, et al.: Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG 2011; 118:1340-1348
28. De Haas M, Finning K, Massey E, Roberts DJ. Anti-D prophylaxis: past, present and future. Transfus Med. 2014; 24:1-17
29. Scheffer PG, de Haas M, van der Schoot CE: The controversy about controls for fetal blood group genotyping by cell-free fetal DNA in maternal plasma. Curr Opin Hematol 2011; 18:467-473
30. Guidelines for blood grouping and red cell antibody testing during pregnancy. British Committee for Standards in Haematology, Blood Transfusion Task Force. Transfus Med 1996; 6:71-74
31. American College of Obstetricans and Gynecologists ACOG Practice Bulletin No. 75: management of alloimmunization during pregnancy. Obstet Gynecol 2006; 108:457-464
32. Moise KJ: Red blood cell alloimmunization in pregnancy. Semin Hematol 2005; 42:169-178
33. McKenna DS, Nagaraja HN, O'Shaughnessy R: Management of pregnancies complicated by anti-Kell isoimmunization. Obstet Gynecol 1999; 93 (5 Pt 1):667-673
34. Leggat HM, Gibson JM, Barron SL, et al.: Anti-Kell in pregnancy. Br J Obstet Gynaecol 1991; 98:162-165
35. van Wamelen DJ, Klumper FJ, de Haas M, et al.: Obstetric history and antibody titer in estimating severity of Kell alloimmunization in pregnancy. Obstet Gynecol 2007; 109:1093-1098
36. Hadley AG: Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn. Transpl Immunol 2002; 10:191-198
37. Engelfriet CP, Ouwehand WH: ADCC and other cellular bioassays for predicting the clinical significance of red cell alloantibodies. Baillieres Clin Haematol 1990; 3:321-337
38. Oepkes D, van Kamp IL, Simon MJ, et al.: Clinical value of an antibody-dependent cell-mediated cytotoxicity assay in the management of Rh D alloimmunization. Am J Obstet Gynecol 2001; 184:1015-1020
39. de Haas M, Koelewijn JM, Bilgin K, et al.: Diagnostic performance of laboratory monitoring to predict severe haemolytic disease of the fetus and newborn in non-RhD-alloimmunised pregnancies; in: Koelewijn JM (ed.): Detection and Prevention of Pregnancy Immunisation. The OPZI Study. Groningen, Drukkerij Van Denderen, 2008:73-85
40. Alfirevic Z, Sundberg K, Brigham S: Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev 2003; (3):CD003252
41. Schonewille H, Klumper FJ, van de Watering LM, et al.: High additional maternal red cell alloimmunization after Rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus. Am J Obstet Gynecol 2007; 196:143-146
42. Mari G, Deter RL, Carpenter RL, et al.: Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342:9-14
43. Oepkes D, Seaward PG, Vandenbussche FP, et al.: Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med 2006; 355:156-164
44. Bettelheim D, Panzer S, Reesink HW, et al.: Monitoring and treatment of anti-D in pregnancy. Vox Sang 2010; 99:177-192
45. van Kamp IL, Klumper FJ, Oepkes D, et al.: Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol 2005; 192:171-177
46. Weisz B, Rosenbaum O, Chayen B, et al.: Outcome of severely anaemic fetuses treated by intrauterine transfusions. Arch Dis Child Fetal Neonatal Ed 2009; 94:F201-F204
47. Lindenburg IT, Smits-Wintjens VE, van Klink JM, et al.: Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol 2012; 206:141-148
48. Connan K, Kornman L, Savoia H, et al.: IVIG - is it the answer? Maternal administration of immunoglobulin for severe fetal red blood cell alloimmunisation during pregnancy: as case series. Aust N Z J Obstet Gynaecol 2009; 49:612-618
49. Fox C, Martin W, Somerset DA, et al.: Early intraperitoneal transfusion and adjuvant maternal immunoglobulin therapy in the treatment of severe red cell alloimmunization prior to fetal intravascular transfusion. Fetal Diagn Ther 2008; 23:159-163
50. Ruma MS, Moise KJ, Kim E, et al.: Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. Am J Obstet Gynecol 2007; 196:138.e1-e6
51. Maisels MJ, McDonagh AF: Phototherapy for neonatal jaundice. N Engl J Med 2008; 358:920-928
52. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114:297-316
53. De Boer IP, Zeestraten EC, Lopriore E, et al.: Pediatric outcome in Rhesus hemolytic disease treated with and without intrauterine transfusion. Am J Obstet Gynecol 2008; 198:54
54. Rath ME, Smits-Wintjens VE, Lindenburg IT, et al.: Exchange transfusions and top-up transfusions in neonates with Kell haemolytic disease compared to Rh D haemolytic disease. Vox Sang 2011; 100:312-316
55. Russel G, Goulden N: Neonatal therapy for haemolytic disease of the newborn; in: Hadley A, Soothill P (eds): Alloimmune Disorders of Pregnancy. Cambridge, Cambridge University Press, 2000:203-218
56. Mundy CA: Intravenous immunoglobulin in the management of hemolytic disease of the newborn. Neonatal Netw 2005; 24:17-24
57. Smits-Wintjens VE, Walther FJ, Lopriore E: Rhesus haemolytic disease of the newborn: postnatal management, associated morbidity and long-term outcome. Semin Fetal Neonatal Med 2008; 13:265-271
58. Rath ME, Smits-Wintjens VE, Lindenburg I, et al.: Top-up transfusions in neonates with Rh hemolytic disease in relation to exchange transfusions. Vox Sang 2010; 99:65-70
59. Mainie P: Is there a role for erythropoietin in neonatal medicine? Early Hum Dev 2008; 84:525-532
60. Rath ME, Smits-Wintjens VE, Lindenburg IT, et al.: Postnatal outcome in neonates with severe Rhesus c compared to Rhesus D hemolytic disease. Transfusion 2012; 53:1580-1585
61. Alcock GS, Liley H: Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev 2002; (3):CD003313
62. Gottstein R, Cooke RW: Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 2003; 88:F6-F10
63. Elalfy MS, Elbarbary NS, Abaza HW: Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn-a prospective randomized controlled trial. Eur J Pediatr 2011; 170:461-467
64. Girish G, Chawla D, Agarwal R, et al.: Efficacy of two dose regimes of intravenous immunoglobulin in Rh hemolytic disease of newborn-a randomized controlled trial. Indian Pediatr 2008; 45:653-659
65. Smits-Wintjens VE, Walther FJ, Rath ME, et al.: Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics 2011; 127:680-686
66. Santos MC, Sa C, Gomes SCJ, et al.: The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double-blind trial. Transfusion 2013; 53:777-782
67. Canadian Blood services: Clinical Guide to Transfusion. Toronto, Canadian Blood Services, 2007
68. Dutch Society of Obstetrics and Gynaecology (in Dutch: NVOG): Erythrocyte Immunisation and Pregnancy. NVOG, 2009
69. Gooch A, Parker J, Wray J, et al.: Guideline for blood grouping and antibody testing in pregnancy. Transfus Med 2007; 17:252-262
70. Branch DR, Shabani F, Lund N, et al.: Antenatal administration of Rh-immune globulin causes significant increases in the immunomodulatory cytokines transforming growth factor-beta and prostaglandin E2. Transfusion 2006; 46:1316-1322
71. Brinc D, Le-Tien H, Crow AR, et al.: IgG-mediated immunosuppression is not dependent on erythrocyte clearance or immunological evasion: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the newborn? Br J Haematol 2007; 139:275-279
72. Kumpel BM: On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. Transfusion 2006; 46:1652-1656
73. Wilson JMG, Jungner G: Principles and Practice of Screening for Disease. Geneva, World Health Organization; Public Health Papers, 1968
74. Koelewijn JM, Vrijkotte TG, de Haas M, et al.: Women's attitude towards prenatal screening for red blood cell antibodies, other than RhD. BMC Pregnancy Childbirth 2008; 8:49
75. Hardy J, Napier JA: Red cell antibodies detected in antenatal tests on rhesus positive women in South and Mid Wales, 1948-1978. Br J Obstet Gynaecol 1981; 88:91-100
76. Bowell PJ, Brown SE, Dike AE, et al.: The significance of anti-c alloimmunization in pregnancy. Br J Obstet Gynaecol 1986; 93:1044-1048
77. Belfrage P, Thomassen P, Floberg J, et al.: Allo-immunization during pregnancy. Clinical results from 1983 to 1989 in a Scandinavian University Hospital. Acta Obstet Gynecol Scand 1992; 71:273-277
78. Heddle NM, Klama L, Frassetto R, et al.: A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy. Transfusion 1993; 33:217-220
79. Gottvall T, Selbing A, Hilden JO: Evaluation of a new Swedish protocol for alloimmunization screening during pregnancy. Acta Obstet Gynecol Scand 1993; 72:434-438
80. Filbey D, Hanson U, Wesstrom G: The prevalence of red cell antibodies in pregnancy correlated to the outcome of the newborn: a 12 year study in central Sweden. Acta Obstet Gynecol Scand 1995; 74:687-692
81. Wong KF, Tse KT, Lee AW, et al.: Is antenatal antibody screening worthwhile in Chinese? Br J Haematol 1997; 97:917-919
82. Howard H, Martlew V, McFadyen I, et al.: Consequences for fetus and neonate of maternal red cell allo-immunisation. Arch Dis Child Fetal Neonatal Ed 1998; 78:F62-F66
83. Rothenberg JM, Weirermiller B, Dirig K, et al.: Is a third-trimester antibody screen in Rh+ women necessary? Am J Manag Care 1999; 5:1145-1150
84. Andersen AS, Praetorius L, Jorgensen HL, et al.: Prognostic value of screening for irregular antibodies late in pregnancy in rhesus positive women. Acta Obstet Gynecol Scand 2002; 81:407-411
85. Lee CK, Ma ES, Tang M, et al.: Prevalence and specificity of clinically significant red cell alloantibodies in Chinese women during pregnancy - a review of cases from 1997 to 2001. Transfus Med 2003; 13:227-231
86. Jovanovic-Srzentic S, Djokic M, Tijanic N, et al.: Antibodies detected in samples from 21, 730 pregnant women. Immunohematology 2003; 19:89-92
87. Ameen R, Al-Eyaadi O, Al-Shemmari S, et al.: Frequency of red blood cell alloantibody in Kuwaiti population. Med Princ Pract 2005; 14:230-234
88. Lurie S, Eliezer E, Piper I, et al.: Is antibody screening in Rh (D)-positive pregnant women necessary? J Matern Fetal Neonatal Med 2003; 14:404-406
89. Adeniji AA, Fuller I, Dale T, et al.: Should we continue screening rhesus D positive women for the development of atypical antibodies in late pregnancy? J Matern Fetal Neonatal Med 2007; 20:59-61
90. Gottvall T, Filbey D: Alloimmunization in pregnancy during the years 1992-2005 in the central west region of Sweden. Acta Obstet Gynecol Scand 2008; 87:843-848
91. Koelewijn JM, de Haas M, Vrijkotte TG, et al.: Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG 2009; 116:1307-1314
92. Koelewijn JM, Vrijkotte TG, de Haas M, et al.: Risk factors for the presence of non-rhesus D red blood cell antibodies in pregnancy. BJOG 2009; 116:655-664
93. Crowther C, Middleton P: Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2000; (2):CD000021
94. Engelfriet CP, Reesink HW, Judd WJ, et al.: Current status of immunoprophylaxis with anti-D immunoglobin. Vox Sang 2003; 85:328-337
95. Crowther CA, Middleton P, McBain RD: Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2013; (2):CD000020
96. Turner RM, Lloyd-Jones M, Anumba DO, Smith GC, Spiegelhalter DJ, Squires H, Stevens JW, Sweeting MJ, Urbaniak SJ, Webster R, Thompson SG: Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality. PLoS ONE 2012; 7:e30711
97. Clausen FB, Christiansen M, Steffensen R, et al.: Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012; 52:752-758
98. Finning K, Martin P, Summers J, et al.: Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008; 336:816-818
99. Muller SP, Bartels I, Stein W, et al.: The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 2008; 48:2292-2301
100. van der Schoot CE, Soussan AA, Koelewijn J, et al.: Non-invasive antenatal RHD typing. Transfus Clin Biol 2006; 13:53-57
101. de Haas M, van der Ploeg CPB, Scheffer PG, Verlinden DA, Hirschberg H, Abbink F, van der Schoot CE: A nation-wide fetal RHD screening programme for targetted antenatal and postnatal anti-D. ISBT Sci Ser 2012; 7:164-167
102. Benachi A, Delahaye S, Leticee N, et al.: Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study. Eur J Obstet Gynecol Reprod Biol 2012; 162:28-32
103. Szczepura A, Bonsel G, Krauth C, et al.: Fetal RHD typing: is fetal RHD typing in all RhD negative women cost effective? BMJ 2008; 336:906
104. Hawk AF, Chang EY, Shields SM, et al.: Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet Gynecol 2013; 122:579-585
105. Cardo L, Garcia BP, Alvarez FV: Non-invasive fetal RHD genotyping in the first trimester of pregnancy. Clin Chem Lab Med 2010; 48:1121-1126
106. Akolekar R, Finning K, Kuppusamy R, et al.: Fetal RHD genotyping in maternal plasma at 11-13 weeks of gestation. Fetal Diagn Ther 2011; 29:301-306
107. Wikman AT, Tiblad E, Westgren M: Noninvasive prenatal screening for RHD: the Stockhom study. ISBT Sci Ser 2012; 7:168-172